What changed
Novo Nordisk presented four OASIS 4 analyses, including post hoc analyses and an indirect comparison. The underlying study included 307 adults without diabetes over 64 weeks.
What the evidence does not settle
Manufacturer account. Exploratory findings are hypothesis-generating; indirect comparison is not head-to-head randomization. Oral semaglutide was investigational for weight management on this date.
Evidence record
Event date: 2025-11-05. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.